Cl-Inhibitor (CO-Inh) is an important inhibitor of the inflammatory response and deficiency of this inhibitor, which may be hereditary or acquired, is associated with recurrent episodes of edema. Recently, an autoimmune form of angioedema has been described that is associated with functional deficiency of C0-Inh and an autoantibody that impedes Cl-Inh function. In this report we describe the isolation of C0-Inh from the monocytes and plasma of a patient with autoimmune angioedema and demonstrate that the patient's monocytes secrete structurally and functionally normal CI-Inh, but show that this protein circulates in the patient's plasma in an inactive, structurally altered form. Furthermore, using analytic gel electrophoresis techniques it is demonstrated that the patient's autoantibody facilitates cleavage of normal Cl-Inh, by its target proteases, to the same species of Cl-Inh that is found circulating in the patient's plasma. This autoantibody facilitated cleavage of normal Cl-Inh is apparently a consequence of destablization of protease/inhibitor complexes. These findings contribute to our understanding of protease/Ci-Inh interactions and document important observations on pathogenic mechanisms in autoimmune disease.
Introduction
Cl-inhibitor (Cl-Inh)' is a heavily glycosylated single chain polypeptide, with a molecular weight of -105 kD, which is synthesized by hepatic and macrophage cells (1, 2) . This protein, which circulates in high levels in human plasma, functions as a serine protease inhibitor and inactivates proteases of the contact phase (activated Hageman factor), kinin (kallikrein), coagulation (Factor XIa), complement (C1, Cir, Cis), and fibrinolytic (plasmin) pathways (2) (3) (4) . Cl-Inh is therefore an important inhibitor of the inflammatory response. Deficiency of Cl-Inh, which may be inherited or acquired, is associated with a number ofbiochemically distinct forms ofangioedema, all of which are characterized by recurrent attacks of episodic edema typically affecting the extremities, abdomen and face (5, 6) . Until relatively recently upper airway obstruc-tion and sudden death was an outcome that could occur in up to 50% of these patients (7) . Although incompletely understood, the attacks of edema appear to be generated by uncontrolled proteins of the complement and kinin pathways possessing potent vasoactive properties (5, 6, 8) .
Angioedema associated with Cl-Inh deficiency most commonly occurs in the clinical setting of an inherited disorder transmitted as an autosomal dominant trait. This hereditary form ofangioedema has two separate expressions one ofwhich is associated with absent or very low levels of normally functioning Cl-Inh and the other with normal or increased levels of a dysfunctional Cl-Inh protein (5, 6) . A rarer form of ClInh deficiency and angioedema known as acquired angioedema has also been described: this typically affects individuals later in life and is associated with very low levels of antigenic Cl-Inh (9) . In contrast to the hereditary type of angioedema, this disorder is characterized by very low levels of the immunoglobulin binding component of complement, Clq (9) . In acquired angioedema, edema is a consequence of enhanced consumption of normally functioning CI-Inh, by ongoing complement activation, which is in general secondary to a malignant process.
Recently we described a patient with an unique form of angioedema, autoimmune angioedema, characterized by normal levels of a dysfunctional Cl-Inh protein and an autoantibody that impedes the function of normal Cl-Inh (10) . In this paper we describe the basic autoimmune process underlying this patient's disorder. It is demonstrated that the patient's monocytes secrete structurally and functionally normal ClInh but that this protein circulates in plasma in an inactive, structurally modified form. It is established in vitro, that patient autoantibody facilitates cleavage of normal Cl-Inh by the proteases Clr, Cls, and plasmin to form a CT-Inh species identical to that isolated from the patient's plasma. Furthermore, it is concluded that the autoantibody mediates this effect by destabilizing the acyl intermediate formed during the interaction of normal Cl-Inh and protease. The high degree of specificity of the patient's autoantibody for normal, uncleaved Cl-Inh and the structural modifications that occur to Cl-Inh on interaction with plasmin are documented.
Methods

Case history
The patient, a 63-yr-old man, presented in March 1982 with intermittent attacks of crampy abdominal pain and edema involving the face, hands, and feet. There was no history of similar episodes in the patient or his family. Physical examination revealed nonpruritic, nonpitting edema of one hand but was otherwise negative. Routine laboratory investigation revealed no abnormality. Antigenic serum levels of complement components Clq and C4 were undetectable; C3 and Cl-Inh were however, present at normal levels. Cl-Inh functional activity was absent. The patient's family had normal complement profiles. A diag-Treatment was commenced with the attenuated androgen, danazol, on an initial daily dose of600 mg tapering to 100 mg over the next 12 mo. All of the patient's complement abnormalities, including ClInh function, quickly reverted to normal and the patient became and remained symptom free for -1 yr. On reduction ofdanazol to 100 mg daily, edema recurred and over the following 12 mo the patient gradually became refractory to treatment with danazol, having recurrent attacks of edema of increasing frequency that were resistant to high dose (600 mg/d) therapy with danazol. These attacks of edema were always predated by 1-2 wk by falling serum levels of C4. Continuing clinical and laboratory evaluation failed to reveal any evidence of underlying disease. Frequent attacks (weekly) of severe edema continued to occur. By this time it was apparent that the patient had a circulating IgG autoantibody that impeded normal CI-Inh function and a treatment regimen of 30 mg prednisolone daily was commenced. Over the next month a gradual clinical response evolved and the patient became symptom free. However, during three attempts that were made to reduce prednisolone dosage below 10 mg daily, edema recurred and this again settled on a higher treatment schedule. One episode of severe facial edema, occurring while the patient was on a reduced dose of prednisolone, arrested promptly on infusion of 1,000 U of CI-Inh concentrate (Immuno-Mycologics, Inc., Norman, OK).
Unfortunately, 2 mo postinfusion of this agent, the patient developed chronic non-A, non-B viral hepatitis, documented by characteristic changes on liver biopsy some 8 mo later. In spite ofthe marked clinical response to prednisolone, the-Clq and C4 serum levels and Cl-Inh functional activity have failed to return to measurable levels. At present the patient remains symptom free on daily therapy of 12 mg prednisolone and 100 mg azathioprine, used as a steroid sparing agent. Now, more than 5 yr postpresentation, no evidence of underlying disease has been detected.
SDS-PAGE
SDS-PAGE using 10% wt/vol acrylamide was performed according to the general method of Laemmli (1 1 (12) . The cells were then washed three times in HBSS and resuspended to 1 X 107 cells/ml in RPMI 1640 containing 20% heat inactivated fetal calf serum. 500 Ml ofthe cell suspension was added to each well ofa 24 well tissue culture plate and the cells incubated for 2 h at 56°C in a humidified atmosphere of 5% CO2. The nonadherent cells were then removed by vigorous washing in RPMI.
Assay ofCl-Inh secreted in culture On days 1, 3, 5, and 7 the culture supernatants were removed and replaced by fresh medium. In some cultures, Escherichia coli derived recombinant y-interferon (Immuneron, BG8201, lot No. 10 M05; Biogen, S.A., Geneva, Switzerland) was used to stimulate monocyte secretion of Cl-Inh (13) . Cl-Inh levels in culture supernatants were measured by an enzyme linked immunoadsorbent assay (14) . The cumulative amounts of Cl-Inh secreted into the culture fluid was found to be linear over the culture period. In order to quantify the number of cells in culture the monolayers were washed on day 7 and the cells lysed in 200 Ml of SDS (0.05%). The DNA content was measured by spectrofluorimetry (15 Isolation of CJ-Inh from plasma ofpatient and normal individuals C1-Inh was prepared from 150 ml of plasma obtained from the patient and a healthy volunteer using minor modifications of previously published procedures (2, 3). All procedures were performed at 4VC. Fractions were monitored for C1-Inh using rocket immunoelectrophoresis with polyclonal rabbit anti human CI-Inh (Dako Corp., Copenhagen, Denmark). Briefly, freshly drawn plasma was made 0.01 M in EDTA and benzamadine. Solid PEG 4000 was added all at once to a final concentration of 5% wt/vol and stirred for 1 h. The supernatant was then applied to a lysine sepharose column (Pharmacia Fine Chemicals, Piscataway, NJ) to remove plasminogen. All ofthe unabsorbed protein was pooled and made 1 mM with PMSF (Sigma), equilibrated with 20 mM sodium phosphate/50 mM NaCl/5 mM EDTA pH 7.0 and applied to a column of DEAE-Sephacel (Pharmacia) equilibrated with the same buffer. Cl-Inh was eluted using a linear gradient made from starting buffer and the same buffer made 300 mM with NaCl. Fractions containing Cl-Inh were pooled, made 1 mM with PMSF, dialyzed against 20 mM Tris-HCl/100 mM NaCl, pH 8.0, and applied to a column of concanavalin A-Sepharose (Pharmacia) equilibrated with the same buffer. Elution was achieved with starting buffer made 0.5% wt/vol with a-methylmannoside (Sigma). Ceruloplasmin, found as a contaminant in the C1-Inh fractions, was removed by repeating the ion exchange chromatography step using DE 52 (Whatman, Inc., Clifton, NJ) in place of the DEAE-Sephacel. The final Cl-Inh preparation was dialyzed against 20 mM Tris-HCl/100 mM NaCl pH 8.0. The concentration of the purified Cl-Inh (normal 0.5 mg/ml, patient 0.5 mg/ml) was determined at 280 nm, assuming an extinction coefficient (I mg/ml) of 3.6 and molecular weight of 105 kD (2, 3 (17) . Fractions were monitored for Cis activity using the substrate Na-carbobenzyoxy-l-lysine-p-nitrophenyl ester (ZLNE) (Sigma). The final preparation was equilibrated against 5 mM triethanolamine-HCl/ 145 mM NaCl, pH 7.4, and stored at -70'C. This Cis Autoantibody Facilitated Cleavage of CF-Inhibitor 699 preparation migrated as a single band of apparent molecular weight 83 kD and was fully activated as determined by analysis of reduced and unreduced samples on SDS-PAGE (18) . The Cis concentration (0.2 mg/ml) was determined at 280 nm assuming an extinction coefficient of 10.5 and molecular weight of 84 kD (19) .
Cir. COr was also isolated by elution from immune complexes (17) . Cir was detected in fractions using rocket electrophoresis with goat anti-human Cir (Atlantic Antibodies, Scarborough, ME). The final Clr preparation was equilibrated with 5 mM triethanolamine-HCI/ 145 mM NaCl, pH 7.4 and stored at 4VC. The Cir preparation migrated on SDS-PAGE as a single band ofapparent molecular weight 87 kD and electrophoresis of reduced and unreduced samples demonstrated the preparation to be fully active. Clr concentration (0.2 mg/ml) was determined at 280 nm assuming an extinction coefficient of 1 1.5 and a molecular weight of 84 kD (19) . This preparation had no activity against the ZLNE and hence contained no contaminating Cis or plasmin.
Plasmin
Plasminogen was prepared from normal plasma using lysine Sepharose affinity chromatography and stored at -70'C (20) . Immediately before use, the plasminogen (0.45 mg/ml) was activated using streptokinase (Hoechst) by incubating at 370C for 15 min using a molar ratio of200:1 plasminogen to streptokinase (21) . The plasminogen was fully activated by this procedure as visualized using SDS-PAGE of reduced and unreduced samples and migrated as a single band of apparent molecular weight 78 kD.
Patient anti Cl-Inh
Antibody. Details of the isolation and characterization of patient antiCl-Inh antibody have been described previously (10) . Antibody concentration (0.8 mg/ml) was measured at 280 nm assuming an extinction coefficient of 13.6 and molecular weight of 150 kD. On SDS-PAGE this antibody migrated as three distinct bands of apparent molecular weight 205-230 kD and a minor band of 150 kD. In the presence ofreducing agents the preparation was apparent as two bands of approximate molecular weights 55 and 25 kD representing the heavy and light chains ofIgG. Electrophoretic transfer ofboth reduced and unreduced SDS-PAGE separated antibody to nitrocellulose and subsequent immunofixing with a y heavy chain specific and with an anti-kappa and anti-lambda antisera (Dako) demonstrated that all of the bands reacted with either anti-heavy chain or anti-kappa antisera but not with anti-lambda. The affinity purified autoantibody is therefore probably monoclonal in nature. However the heterogenous nature of the antibody on SDS-PAGE could be indicative of an antibody of oligoclonal origin, or more probably, may represent immunoglobulin fragments or aggregates generated during its purification. The affinity purified antibody had no enzymatic activity when tested with the substrate ZLNE. The subclass of the antibody (IgGs-1) was determined using single radial immune diffusion and monoclonal antibodies to the IgG subclasses 1-4 (Oxoid Ltd., Basinstoke, England).
Studies on patient and normal Cl-Inh isolatedfrom plasma
The purity and molecular weight of patient and normal Cl-Inh was assessed using SDS-PAGE. The functional integrity of patient and control Cl-Inh was assessed by measuring its ability to prevent the colorimetric conversion ofthe substrate ZLNE by purified Cis (2) and also by their ability to form stable complexes, visualized using SDS-PAGE, with the purified enzymes Cis, Cir, and plasmin. Equimolar quantities of patient (0.5 mg/ml) and normal (0.5 mg/ml) Cl-Inh were incubated separately at 37°C in 0.02 M sodium phosphate/100 mM NaCl pH 7.2 (PBS) with Cis (0.2 mg/ml), Cir (0.2 mg/ml) and plasmin (0.45 mg/ml). At the end of 15-and 30-min incubation periods identical aliquots, calculated to contain -1 ug of both inhibitor and protease, were incubated in sample buffer with and without 2-mercaptoethanol and boiled for 4 min. Samples were then analyzed using SDS-PAGE and the proteins visualized with silver stain.
Studies on the interaction ofpatient antibody, normal CJ-Inh, and protease Normal CI-Inh was incubated with affinity purified anti CI-Inh antibody in a molar ratio of 1:2 (inhibitor to antibody) at 370C for 15 min.
At the end of this incubation period aliquots of the reaction mixture were removed and incubated separately with each purified protease in a molar ratio of 1:1, inhibitor to protease, at 370C for 15 and 30 min.
The following controls were included: equimolar amounts of native inhibitor and each protease; antibody treated inhibitor and PBS; native inhibitor and PBS; protease with PBS; and affinity purified antibody alone. At the end of the reaction period, aliquots containing the same amounts of CI-Inh and protease per aliquot were removed and boiled in sample buffer with and without reducing agents for 4 min.
To study the effect of antibody on CI-Inh/protease complexes, CI-Inh was preincubated with Cis for 15 min and then exposed to antibody and incubated for 15 and 30 min as above.
Kinetic studies on the mechanism ofinteraction of protease, antibody, and normal CJ-Inh
To study the mechanism and sequence of reaction between CI-Inh, protease and antibody, kinetic studies were performed using the proteases Cis, Cir, and plasmin. Equimolar quantities of protease and native inhibitor were incubated in PBS, pH 7.2, at 370C. At the same time, equimolar quantities of antibody treated inhibitor (molar ratio 2:1 antibody to inhibitor) and protease were incubated under the same conditions. Aliquots ofthese reaction mixtures were withdrawn at time intervals ranging from 10 s to 45 min and immediately analyzed using SDS-PAGE.
Studies on the specificity ofaffinity purified patient antibody Affinity purified patient autoantibody was labeled with I125 using Enzymobead radioiodination reagent (Bio-Rad Laboratories), according to the manufacturer's instructions. Sephadex G25 (Pharmacia) was used for the separation of bound and free iodine. Patient plasma C1-Inh, normal plasma Cl-Inh, al protease inhibitor (Sigma), antithrombin III (Boehringer Mannheim, Indianapolis, IN), ovalbumin (Sigma) and bovine serum albumin (DiaMed AG, Morat-Murten, Switzerland) were separately linked to cyanogen bromide activated Sepharose at a concentration of I mg of protein/ml of packed Sepharose. Greater than 95% binding of each protein to the Sepharose was achieved. Unoccupied sites on the activated Sepharose were blocked using 0. band with an apparent molecular weight of 96 kD was also present in trace amounts under nonreducing conditions. The increased mobility of normal C1-Inh on SDS gels in the presence of reducing agents has been noted by other workers (22, 23) . Patient Cl-Inh isolated from plasma also migrated as a single band on SDS-PAGE but in contrast had an apparent molecular weight of 96 kD under both reducing and non reducing conditions (tracks 4 and 5, respectively [ Fig. 2]) . Thus Cl-Inh isolated from patient's plasma had a lower apparent molecular weight than normal Cl-Inh, irrespective ofthe presence or absence of reducing agents. 1 3, respectively, Fig. 2 ). An additional Functional activity ofpatient plasma CJ-Inh Patient inhibitor isolated from plasma had no inhibitory activity against Cis as assessed using the esterolytic assay. The functional activity of the patient's C1-Inh was also examined by measuring its ability to form SDS stable complexes with the purified proteases electrophoresed in the absence of reducing agents. These experiments are illustrated in Fig. 3-5 , tracks 1-8. In Fig. 3 The sequence of reaction of normal C1-Inh with plasmin is illustrated in Fig. 7, tracks 1-9 . It is evident from these tracks that 104 kD inhibitor was formed from 115 kD inhibitor within lO s ofincubation (track 1). Visible complexes (209 kD) appear between Cl-Inh and plasmin when an incubation period of 2 min had elapsed (track 3). In the following tracks (with a time span of 2-45 min) there was a reduction in the quantity of 1 5 kD inhibitor, an initial increase in the quantity of 104 kD Cl-Inh followed by a diminution ofthis species and a small amount of 83 kD Cl-Inh generated throughout the reaction period. The reaction between C1-Inh bound by patient antibody and plasmin is shown in tracks [10] [11] [12] [13] [14] [15] [16] [17] [18] Figure 7 . Kinetic study of the interaction of normal Cl-Inh, patient autoantibody and plasmin. Normal Cl-Inh and plasmin were incubated at 37°C and aliquots were removed at time intervals of 10 s to 45 min and separated using 10% SDS-PAGE in the absence of reducing agents, tracks 1-9. Normal Cl-Inh pretreated with patient autoantibody was also incubated under the same conditions with plasmin, aliquots were removed at the same time intervals and analyzed on the same gel, tracks 10-18. Tracks 1, 10 are the proteins incubated for a period of 10 s; tracks 2, 11 for 60 s; tracks 3, 12 for 2 min; tracks 4, 13 for 3 min; tracks 5, 14 for 4 min; tracks 6, 15 for 5 min; tracks 7, 16 for 15 min; tracks 8, 17 for 30 min; tracks 9, 18 for 45 min. that this increased in quantity from track 10 to 16 (10 s to 15 min) and thereafter showed a decrease to the end of the incubation period. 96 kD Cl-Inh is apparent in track 11 and also decreases in quantity at the end ofthe reaction period. After an incubation period of 4 min (track 14), a sharp increase in the quantity of 83 kD Cl-Inh was apparent that increased in quantity to the end of the reaction period.
It is evident therefore from each of these experiments that the formation of cleaved Cl-Inh in the presence of antibody was occurring after complexes first appeared between normal Cl-Inh and enzyme in the absence of antibody and consequently they are likely to be closely related events.
As can be seen from Fig. 7 in the absence of antibody normal Cl-Inh complexes with plasmin and 104-and 83-kD Cl-Inh species are generated. In the presence of autoantibody, however, a new species ofCl-Inh at 96 kD is apparent which is followed by a sharp increase in the presence of 83 kD C1-Inh.
This 96-kD species produced by plasmin in the presence of patient autoantibody is the same molecular weight species as patient CT-Inh, which as already shown is rapidly cleaved by plasmin to an 83-kD species. Furthermore, in a separate experiment we incubated normal Cl-Inh with plasmin over various time intervals, terminated the reaction with soya bean trypsin inhibitor, and then further incubated with Cls and have demonstrated that the species of cleaved C1-Inh produced by plasmin in the absence of antibody is functionally active (results not illustrated).
The interaction between plasmin and CJ-Inh is therefore more complicated than that which occurs between C1-Inh and other proteases. Harpel and Cooper have previously described the generation of two species of 96 kD Cl-Inh during its encounter with plasmin, one of which retained functional activity (24) . A further cleavage product of C1-Inh of 85 kD may also be generated by plasmin (25 (2) (3) (4) (27) (28) (29) (30) (31) . It is thought, based largely on information derived from studies involving SDS-PAGE, that inhibitors of this class rapidly inactivate target proteases by forming tightly bound equimolar inhibitor/protease complexes. It has been observed in vitro that during the interaction of C1-Inh with target protease, modified inactive inhibitor may be generated with an apparent molecular weight lower than that observed for native inhibitor (4, 22, 23, 32) .
Under the conditions described in this report normal ClInh migrates with an apparent molecular weight of 115 kD in the absence of reducing agents and 105 kD in the presence of reducing agents. It was also demonstrated that normal CI-Inh may be converted to a 96-kD species following interaction with protease and autoantibody and furthermore, that the molecular weight ofthis species was not altered by the presence of reducing agents. Patient plasma Cl-Inh also migrated with a molecular weight of 96 kD irrespective of the presence or absence of reducing agents. Therefore both patient plasma CiInh and normal Cl-Inh modified by protease and autoantibody are distinct from the 105-kD Cl-Inh produced from normal C1-Inh by the use ofreducing agents. Thus, differences in mobility between reduced normal C1-Inh and reduced ClInh after interaction with protease can best be explained by a difference in the primary structures (i.e., molecular size) of the two species. Hence, it is apparent that the structural basis of the generation of modified C1-Inh during encounter with protease does not simply involve an alteration in the secondary structure of the molecule and is almost certainly the result of proteolytic cleavage and release of a small peptide of -4 kD molecular weight from the parent molecule. This cleavage of the Cl-Inh molecule probably occurs at the arginine-threonine residues, 444-445 as numbered by Bock et al. (29) .
It has been shown that patient monocytes secrete structurally and functionally normal Cl-Inh. It was also demonstrated however, that this protein circulates in plasma in an inactive, structurally altered form with an apparent molecular weight of 96 kD. It has previously been observed in vitro that 96 kD Cl-Inh may be generated from 105 kD CJ-Inh during encounter with protease. Furthermore, Zuraw and Curd have demonstrated that this occurs to a limited extent in vivo as part of the normal catabolism of C1-Inh since small quantities of modified CT-Inh were found circulating in the plasma of normal individuals (25) . Therefore, it is highly probably that the 96-kD Cl-Inh found circulating in this patient's plasma has been produced in vivo by protease interaction with the normal species of Cl-Inh secreted by the patient's monocytes and hepatocytes. As all of the patient's Cl-Inh circulates as a 96-kD species, a highly efficient in vivo mechanism must exist for the conversion of the normal species of Cl-Inh to the structurally modified, inactive form. The presence of an autoantibody in the patient's circulation which bound to normal Cl-Inh, suggested that an autoimmune mechanism was responsible for the generation of this dysfunctional Cl-Inh. In this report, experiments are described that investigate the generation of 96 kD Cl-Inh from normal (105 kD) Cl-Inh following inhibitor, protease, and autoantibody interaction. It was found that patient autoantibody promoted cleavage of normal Cl-Inh to a 96-kD species with each of the proteases that were investigated: Clr, Cis, and plasmin.
The precise mechanism by which autoantibody mediated this effect was also investigated and it was shown that patient antibody greatly diminished the quantity of stable complexes formed during Cl-Inh protease interaction. Furthermore, it was demonstrated kinetically, that autoantibody facilitated cleavage of C1-Inh was occurring at the same time or subsequent to complex formation between the inhibitor and protease. Hence, patient autoantibody apparently mediates its effect by binding to normal Cl-Inh, altering its conformation and consequently causing destabilization of the acyl intermediate normally formed between protease and inhibitor. The demonstration that patient autoantibody facilitated cleavage ofnormal C1-Inh by each ofthe target proteases we have tested is a novel observation, at the molecular level, on the pathogenesis of autoimmune disease. The patient's autoantibody was shown to react with normal uncleaved C1-Inh but not with patient's cleaved CJ-Inh. Furthermore autoantibody had no effect on Cl-Inh if it was added after Cl-Inh/protease interaction. That the antibody has a highly restricted specificity is further illustrated by its failure to react with the other members of the serpin family that have been tested. Support for the suggestion that the three dimensional structure of modified inactive C1-Inh is altered from that of the native molecule is provided by Nuijens et al. (33) who prepared a monoclonal antibody reactive with modified inactive CT-Inh but not with the native molecule.
Since our initial report (and during the preparation of this manuscript), five other cases of angioedema with anti Cl-Inh antibodies have been described (34, 35) . The authors of one of these reports suggest that Cis is solely responsible for the inactivation of Cl-Inh in the presence of patient autoantibody (34) . In contrast to our studies, these authors utilized unfractionated serum or plasma to study cleavage products of radiolabeled Cl-Inh. In contrast to the autoantibody we have described, one of the autoantibodies described by Alsenz et al. reacts with patient Cl-Inh (34) . It is therefore probable that a spectrum of autoantibodies exists in autoimmune angioedema having unique specificities for sites on C1-Inh. This could result in preferential cleavage of CJ-Inh by different proteases with each particular autoantibody. Our studies clearly show that our patient's autoantibody mediates cleavage of normal C1-Inh with each of the proteases we have tested.
The antibody we have described is apparently monoclonal in nature and is specific for a site close to or at the reactive site of normal Cl-Inh. There is some evidence that the anti Cl-Inh antibodies described in some ofthe other cases ofautoimmune angioedema may also be monoclonal or oligoclonal in nature (34) . Monoclonal immunoglobulins have also been observed in association with the previously describe form of acquired angioedema (9) . There is therefore a striking association between all forms of acquired angioedema and monoclonal gammopathy. Furthermore Cl-Inh has been shown to circulate as an 96-kD species in acquired angioedema (25) and these patients also have depressed Clq. At this stage it is unclear whether or not there is a closer relationship between autoimmune angioedema and this more common form of acquired angioedema, which is thought to be associated with antiidiotypic antibodies (36).
Kallikrein and activated Hageman factor in particular have also been implicated in the pathogenesis of angioedema and modified Cl-Inh may be produced on interaction with these proteases (22, 25, (37) (38) (39) . Therefore Cl-Inh may have a com-mon mechanism of inactivation with all of its target proteases and consequently in vivo, the autoantibody may facilitate destabilization of each of the acyl intermediates formed during each protease/Cl-Inh interaction.
Autoimmune angioedema is therefore a new autoimmune disease the biochemical hallmarks ofwhich are low serum Clq and C4 levels, and absent functional CJ-Inh activity in the presence of normal or slightly reduced serum antigenic levels. As in most cases ofautoimmune disease, it is unclear what has induced the production ofanti C1-Inh antibody. Complement activation after an infection, for example, may have exposed a site on C1-Inh in the vicinity of the reactive site that is not normally accessible to the immune response.
The normal remittive agents that were used in the treatment of angioedema produced only a transient clinical response in this patient's case. However, treatment with agents of proven value in modulation of autoimmune disorders has induced a lasting clinical remission. This remission has occurred without a change in the level of circulating antibody (data not included) or a recovery in the serum levels of C4, Clq, or functional CI-Inh activity. That remission has been induced by this therapy is supported by the recurrence of the edema on the three separate occasions when attempts were made to reduce prednisolone dosage. The precise mechanism by which this therapy has mediated the cessation of attacks of edema is unknown.
In summary, we have described the mechanism by which an autoantibody to C1-Inh, found in a patient with autoimmune angioedema, mediates CI-Inh dysfunction. These findings contribute to our understanding of the mechanisms of interaction between CT-Inh and proteases. They also represent novel observations on pathogenic mechanisms in autoimmune disease and have important implications in the management of complement-mediated angioedema.
